StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.24−0.04 (-13.70%)

Close on Nov 20, 2026Market cap $3.13MP/E –Yield –

Lantern Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lantern Pharma's free cash flow for the twelve months ending Dec 31, 2025 was -$15.68M. For fiscal 2025 it was -$15.68M. The highest annual figure on record is -$10.61M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.68M–
FY2024Dec 31, 2024-$17.83M–
FY2023Dec 31, 2023-$14.37M–
FY2022Dec 31, 2022-$12.80M–
FY2021Dec 31, 2021-$10.61M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$2.79M–
Q3 FY2025Sep 30, 2025-$4.57M–
Q2 FY2025Jun 30, 2025-$3.94M–
Q1 FY2025Mar 31, 2025-$4.38M–
Q4 FY2024Dec 31, 2024-$3.97M–
Q3 FY2024Sep 30, 2024-$5.59M–
Q2 FY2024Jun 30, 2024-$5.19M–
Q1 FY2024Mar 31, 2024-$3.07M–
Q4 FY2023Dec 31, 2023-$3.39M–
Q3 FY2023Sep 30, 2023-$3.62M–
Q2 FY2023Jun 30, 2023-$3.59M–
Q1 FY2023Mar 31, 2023-$3.77M–
Q4 FY2022Dec 31, 2022-$2.68M–
Q3 FY2022Sep 30, 2022-$4.04M–
Q4 FY2021Dec 31, 2021-$2.04M–
Q3 FY2021Sep 30, 2021-$4.69M–

More Lantern Pharma figures

See a number that looks wrong?